RadNet Stock Surges 6.3% - Analysts Weigh In

Shares of the medical imaging company RadNet jumped after a strong earnings report, but is it time to buy?

Apr. 16, 2026 at 5:07pm

Got story updates? Submit your updates here. ›

An extreme close-up of the gears, sensors, and metal components that make up the internal machinery of a medical imaging device, conveying the technical sophistication and industrial scale of RadNet's operations.RadNet's advanced imaging equipment and robust infrastructure underpin the company's leading position in the medical diagnostics industry.Los Angeles Today

Shares of RadNet, Inc. (NASDAQ:RDNT) rose 6.3% on Thursday, trading as high as $62.12 per share. The jump came after the medical imaging company reported better-than-expected earnings, with revenue up 14.8% compared to the same quarter last year. Several analysts have issued new price targets on the stock, ranging from a low of $58 to a high of $91.

Why it matters

RadNet is a leading independent provider of outpatient diagnostic imaging services in the United States, operating a nationwide network of imaging centers. The company's strong financial performance and analyst optimism suggest the stock could have further upside potential, making it an interesting investment opportunity in the healthcare sector.

The details

RadNet reported earnings of $0.23 per share, beating analysts' consensus estimate of $0.19. The company's revenue for the quarter was $547.71 million, up from $515.67 million in the year-ago period. RadNet has a debt-to-equity ratio of 0.79 and a current ratio of 1.76, indicating a healthy financial position. The stock's 50-day simple moving average is $63.37, and its 200-day simple moving average is $71.60.

  • RadNet reported earnings on Monday, March 2, 2026.
  • The stock price jumped 6.3% on Thursday, April 16, 2026.

The players

RadNet, Inc.

A leading independent provider of outpatient diagnostic imaging services in the United States, operating a nationwide network of imaging centers.

Jefferies Financial Group

A research firm that has issued a 'buy' rating and a $91.00 price target on RadNet shares.

KeyCorp

A research firm that has raised its rating on RadNet to 'strong-buy'.

Raymond James Financial

A research firm that has reissued a 'strong-buy' rating on RadNet.

Truist Financial

A research firm that has set a $90.00 target price on RadNet shares.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

What’s next

Analysts will continue to monitor RadNet's financial performance and provide updated price targets and recommendations as the company navigates the evolving healthcare landscape.

The takeaway

RadNet's strong earnings and analyst optimism suggest the stock could be a compelling investment opportunity for investors looking to gain exposure to the growing medical imaging industry. However, the company's debt levels and competitive landscape will be important factors to consider.